Live Breaking News & Updates on Financial Dynamics|Page 1
Stay updated with breaking news from Financial dynamics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Happened with astrazeneca, what is your best estimate for when a safe vaccine will be available . Dr. Redfield one thing i have learned is the cdc director, i business. The opinion im in the data and signs of it. What does the data and signs suggest . Dr. Redfield based on enrollment right now that is going on with the pfizer and moderna, that it is conceptual that they will have enough data to present it to the fda for evaluation somewhere before the end of october and the end of november. The reason i cannot be more specific is because these trials are event driven trials. They are 100 dependent on how much covid occurs in the volunteer population. If it is a lot of these individuals having to get covid independent of what group they are in, and the potential for them to have enough events if the vaccine is very efficacious will be in the october timeframe. If the vaccine is 50 efficacious, it might be in the late november timeframe. If there are fewer events and it vaccine, andd mig ....
A government review in early october. Moderna had talked about a phase three trial in september. Astrazeneca before this is in phase three. Backdrop and what happened with astrazeneca, what is your best estimate for when a safe vaccine will be available . Dr. Redfield one thing i have learned is the cdc director, i business. The opinion im in the data and signs of it. What does the data and signs suggest . Dr. Redfield based on enrollment right now that is going on with the pfizer and moderna, that it is conceptual that they will have enough data to present it to the fda for evaluation somewhere before the end of october and the end of november. The reason i cannot be more specific is because these trials are event driven trials. They are 100 dependent on how much covid occurs in the volunteer population. If it is a lot of these individuals having to get covid independent of what group they are in, and the potential for them to have enough events if the vaccine is very efficacious will ....
One thing i learned, the cdc director, not in the opinion business, the data and science. When does the date and science exists . Based on enrollment with pfizer and moderna it is conceptual that they will have enough data to present it to the fda for evaluation before october toward the end of november. The reason they cant be more specific is these trials are event driven trials, they are 100 dependent on how much covid19 occurs in the volunteer population. A lot of the individuals, a total number of events the potential for them to have enough events, the vaccine will be in the october time frame, the vaccine is 50 it might be in the late november timeframe. If there are fewer events and a good vaccine, might be in the November December timeframe. Somewhere between the end of october and end of the year it is probable one or more of these vaccines will be presented to the fda for review, emergency authorization or potentiall ....
Not in theop opinion business. Im into the science of it. So when does the data and client suggest . Based on enrollment right now with pfizer and turner, it is conceptualgofi that they will he enough data to present it for evaluation somewhere before the end of october and november. The reason i cant be so specific is because they are event driven trials so they are one 100 dependent on how much covid occurs in the volunteer population. A lot of these individuals to get covid might depend upon which group they are in, the potential for them to have enough events if the vaccine has these indications will be in the october timeframe. Its the vaccine 50 by cases, it might be late november. Theres fewer events and its a good vaccine, it might be late november, december timeframe so i think we can all say summer between end of october and the end of the year, its probable one or more vaccine will be presented to the fda for review either for emergency authorization or potentially this. So ....
America, the director talked about covid19 trials, the virus impact on minority communities and issues with politicizing the cdc. This is 30 minutes. The cdc had guidance not that long ago about a vaccine with the state healt Health Agency ay said it was on track for government review imager not had talked about phase three trial in september astrazeneca talked about vaccine in october. Against the backdrop and this happened from astrazeneca what is your best estimate with a safe vaccine being available. One thing i learned is a cdc director, im not in the opinion business im in the data and science. When does the data suggest. Based on whats going on with pfizer imager not that it is conceptual and they will have enough data to present it to the fda for evaluation somewhere before the end of october and the end of november. The reason i cannot be more specific is these trials are event driven trials in the really 100 dependent on ....